Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial

BACKGROUND: Immunoglobulin A nephropathy (IgAN) is the most common cause of glomerulonephritis worldwide, and the optimal approach to its treatment remains a significant challenge. METHODS: We did a prospective, randomized, open-labeled, multicenter, controlled trial, comprised of 3-month run-in, 12...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Zhaohui, Zhang, Zhen, Yu, Zanzhe, Lu, Fuming, Mei, Changlin, Ding, Xiaoqiang, Yuan, Weijie, Zhang, Wei, Jiang, Gengru, Sun, Min, He, Liqun, Deng, Yueyi, Pang, Huihua, Qian, Jiaqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381933/
https://www.ncbi.nlm.nih.gov/pubmed/34396911
http://dx.doi.org/10.1080/0886022X.2021.1963775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381933/
https://www.ncbi.nlm.nih.gov/pubmed/34396911
http://dx.doi.org/10.1080/0886022X.2021.1963775

Ejemplares similares